Vesalius Biocapital has held a final close on €120m for Vesalius Biocapital III after more than two years on the road.
The vehicle was launched in March 2017 and held a first close on €65m in May 2017, and an interim close on €110m in January this year. It had a target of €150m.
The fund's predecessor, Vesalius Biocapital II, held a final close on €80m against a €100m target in 2013.
The fund attracted commitments from investors in Europe, the Americas, the Middle East and North Africa. The European Investment Fund made a €30m commitment to the vehicle.
The fund has completed three investments to date: Portuguese medical equipment business Sword Health in April 2018; Finnish pharmaceutical company Forendo Pharma in September 2018; and German medical technology firm Mecuris in January this year.
It will continue investing in later-stage European life-sciences companies in drug development, medtech, diagnostics and digital health with the goal of building a portfolio of 10-15 companies.
Versalius Biocapital – Christian Schneider, Stéphane Verdood (managing partners).
Italian mid-market firm Progressio held an interim close on €185m back in February
Fresh capital will support product innovation and European expansion for the Spanish startup
Outsourced drug development company has expanded into the US and tripled its revenues under GHO
GP buys majority in Netherlands-based software testing and quality assurance specialist